Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 7/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.38 |
| ▸ | NPY1R | P25929 | 5/20 | 0.38 |
| ▸ | NPY2R | P49146 | 3/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.37 |
| ▸ | ITGAV | P06756 | 3/20 | 0.37 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283125 | 0.95 | EPHX2 (0.38) | EPHX2C3AR1F10NPY4RNPY5R | |
| SCHEMBL5965846 | 0.95 | QRFPR (0.40) | EPHX2C3AR1F10NPY4RNPY5R | |
| SCHEMBL243189 | 0.77 | PTAFR (0.41) | EPHX2ITGB3ITGA2BITGAV | |
| Benzene SCHEMBL6278673 | 0.75 | C3AR1 (0.49) | EPHX2C3AR1NPY4RNPY5RNPY1R | |
| SCHEMBL243198 | 0.74 | EPHX2 (0.37) | EPHX2ITGB3ITGA2BITGAVCYP2C9 | |
| SCHEMBL25601934 | 0.73 | F10 (0.44) | F10NPY4RNPY5RNPY1R | |
| SCHEMBL29875780 | 0.73 | SLC15A2 (0.44) | C3AR1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL3952951 | 0.73 | SLC15A2 (0.44) | C3AR1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29875467 | 0.73 | SLC15A2 (0.44) | C3AR1NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL3952924 | 0.73 | SLC15A2 (0.44) | C3AR1NPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503749-A4 | METHIONINE AMINOPEPTIDASE-2 INHIBITORS AND METHODS OF USE THEREOF | PRAECIS PHARM INC (US) | 2008-04-09 | — | — | EP | disclosed |
| US-6919307-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050130903-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | GLAXOSMITHKLINE LLC | 2005-06-16 | — | — | US | disclosed |
| US-20050059585-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS INC. (US) | 2005-03-17 | — | — | US | disclosed |
| EP-1503749-A2 | METHIONINE AMINOPEPTIDASE-2 INHIBITORS AND METHODS OF USE THEREOF | Praecis Pharmaceuticals Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003092608-A2 | METHIONINE AMINOPEPTIDASE-2 INHIBITORS AND METHODS OF USE THEREOF | PRAECIS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| EP-1330447-A2 | PEPTIDES AS MET-AP2 INHIBITORS | Praecis Pharmaceuticals Incorporated (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030109671-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS INC. | 2003-06-12 | — | — | US | disclosed |
| US-20020151493-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS INC. | 2002-10-17 | — | — | US | disclosed |
| WO-2002042295-A2 | PEPTIDES AS MET-AP2 INHIBITORS | PRAECIS PHARMACEUTICALS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109671-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | EPHX2 898/4885C3AR1 419/4885F10 1250/4885 |
| US-20050130903-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | EPHX2 898/4885C3AR1 419/4885F10 1250/4885 |
| US-20050059585-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, LNPEP | EPHX2 632/4885C3AR1 1371/4885F10 2394/4885 |
| US-20020151493-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | EPHX2 898/4885C3AR1 419/4885F10 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.